APYX MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVIONBy ApyxMedical|2025-12-12T19:11:47+00:00January 3, 2023|2023 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN THE PIPER SANDLER 34TH ANNUAL HEALTHCARE CONFERENCEBy ApyxMedical|2025-12-12T19:12:19+00:00November 22, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:12:51+00:00November 10, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON NOVEMBER 10, 2022By ApyxMedical|2025-12-12T19:13:25+00:00September 26, 2022|2022 Shareholder News, J-Plasma, Renuvion|
‘BOTCHED’ TV STAR DR. PAUL NASSIF AMONG TOP U.S. PLASTIC SURGEONS USING RENUVION HELIUM PLASMA TECHNOLOGY IN COSMETIC PROCEDURESBy ApyxMedical|2025-12-12T19:13:52+00:00September 13, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN THE LAKE STREET BEST IDEAS GROWTH CONFERENCEBy ApyxMedical|2025-12-12T19:14:14+00:00September 6, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:14:42+00:00August 11, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION RELEASES ENVIRONMENTAL, SOCIAL AND GOVERNANCE DATA IN NEW TEAR SHEETBy ApyxMedical|2025-12-12T19:15:08+00:00July 27, 2022|2022 Shareholder News, J-Plasma, Renuvion|
RENUVION CLEARED BY FDA FOR NECK LAXITY PROCEDURES OFFERING PATIENTS A MINIMALLY INVASIVE OPTION TO ELIMINATE SAGGING NECKBy ApyxMedical|2025-12-12T19:15:31+00:00July 18, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO IMPROVE APPEARANCE OF LAX (LOOSE) SKINBy ApyxMedical|2025-12-12T19:15:55+00:00July 18, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES RESULTS OF THE U.S. IDE CLINICAL STUDY EVALUATING THE USE OF RENUVION TO IMPROVE THE APPEARANCE OF LAX SKIN IN THE NECK AND SUBMENTAL REGIONBy ApyxMedical|2025-12-12T19:16:26+00:00July 8, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON AUGUST 11, 2022By ApyxMedical|2025-12-12T19:16:50+00:00June 30, 2022|2022 Shareholder News, J-Plasma, Renuvion|
RENUVION DERMAL HANDPIECE FOR WRINKLE-REDUCTION PROCEDURES CLEARED BY FDABy ApyxMedical|2025-12-12T19:17:12+00:00June 28, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION COSMETIC TECHNOLOGY IN DERMAL RESURFACING PROCEDURESBy ApyxMedical|2025-12-12T19:17:54+00:00May 26, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN JUNEBy ApyxMedical|2025-12-12T19:18:17+00:00May 25, 2022|2022 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:18:44+00:00May 12, 2022|2022 Shareholder News, J-Plasma, Renuvion|
